Mark S. Levine - Jan 26, 2024 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Signature
/s/ Eva Renee Barnett, attorney-in-fact for Mark S. Levine
Stock symbol
IMVT
Transactions as of
Jan 26, 2024
Transactions value $
-$114,778
Form type
4
Date filed
1/29/2024, 04:12 PM
Previous filing
Nov 24, 2023
Next filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale -$113K -2.98K -0.97% $37.91 304K Jan 26, 2024 Direct F1, F2
transaction IMVT Common Stock Sale -$1.77K -46 -0.02% $38.45 304K Jan 26, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on January 19, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.44 - $38.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.45 - $38.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.